ストックスクリーナーアプリを入手
16.11
13.53%
-2.52
プレマーケット:
16.50
0.39
+2.42%
前日終値:
$18.63
開ける：
$18.49
24時間の取引高:
853.94K
Relative Volume:
1.23
時価総額：
$672.63M
収益：
$5.92M
当期純損益:
$-75.79M
株価収益率:
-7.6203
EPS:
-2.1141
ネットキャッシュフロー:
$-59.15M
1週間 パフォーマンス:
-24.08%
1か月 パフォーマンス:
-25.28%
6か月 パフォーマンス:
+203.39%
1年 パフォーマンス:
+254.85%
1日の値動き範囲:
$15.68
$18.71
1週間の範囲:
$15.68
$21.09
52週間の値動き範囲:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.11 | 672.63M | 5.92M | -75.79M | -59.15M | -2.1141 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | Oppenheimer | Outperform |
| 2026-02-18 | アップグレード | Jefferies | Hold → Buy |
| 2026-01-27 | 開始されました | Piper Sandler | Overweight |
| 2025-12-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | アップグレード | Citigroup | Neutral → Buy |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-12-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-21 | 開始されました | Citigroup | Buy |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-21 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioage Labs Inc (BIOA) 最新ニュース
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Chipmakers Recap: Can BioAge Labs Inc lead its sector in growth2026 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BioAge Highlights BGE-102 Progress and Financial Strength - TipRanks
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
BioAge Labs (NASDAQ: BIOA) widens 2025 loss but extends cash runway to 2029 - Stock Titan
BioAge says oral drug cut a heart-risk marker 86% in Phase 1 - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Certain Warrant of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
Certain Common Stock of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
BioAge Labs, Inc.: Fundamental Analysis and Financial Ratings | Y7G | US09077V1008 - marketscreener.com
If You Invested $1,000 in BioAge Labs Inc. (BIOA) - Stock Titan
Jefferies upgrades BioAge Labs (BIOA) - MSN
BioAge Labs (NASDAQ:BIOA) Trading Down 5.9%What's Next? - MarketBeat
BioAge Makes a Comeback, Yet Technical Indicators Lean Bearish - Bitget
Can BioAge Labs Inc expand its profit marginsMarket Performance Summary & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Up 8.8%Should You Buy? - MarketBeat
BIOAGE Labs Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quarterly Recap: Will BioAge Labs Inc outperform small cap indexesTrade Volume Summary & Daily Entry Point Alerts - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup - MarketBeat
Aug Update: Will BioAge Labs Inc outperform small cap indexesEarnings Recap Report & Smart Swing Trading Techniques - baoquankhu1.vn
Bioage Labs Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
BioAge Labs (BIOA) price target increased by 24.14% to 12.24 - MSN
Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat
BIOA (NASDAQ: BIOA) insider files Form 144 showing multiple sales - Stock Titan
Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn
Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance
Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal - TipRanks
Bioage Labs Inc (BIOA) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
1.88%
大文字化:
|
ボリューム (24 時間):